BusinessWire -- NCCN recently received two individual $2 million research grants from GlaxoSmithKline to evaluate the effectiveness of ofatumumab in hematologic malignancies and pazopanib in the treatment of solid tumors. Investigators from NCCN Member Institutions are eligible to apply for the research funding.
